ATE460479T1 - Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon - Google Patents

Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon

Info

Publication number
ATE460479T1
ATE460479T1 AT03798512T AT03798512T ATE460479T1 AT E460479 T1 ATE460479 T1 AT E460479T1 AT 03798512 T AT03798512 T AT 03798512T AT 03798512 T AT03798512 T AT 03798512T AT E460479 T1 ATE460479 T1 AT E460479T1
Authority
AT
Austria
Prior art keywords
adamts
antibody
cliping
antibodies
assay system
Prior art date
Application number
AT03798512T
Other languages
English (en)
Inventor
Kenji Soejima
Noriko Mimura
Hiroaki Maeda
Chikateru Nozaki
Takayoshi Hamamoto
Tomohiro Nakagaki
Original Assignee
Chemo Sero Therapeut Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeut Res Inst filed Critical Chemo Sero Therapeut Res Inst
Application granted granted Critical
Publication of ATE460479T1 publication Critical patent/ATE460479T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT03798512T 2002-09-25 2003-09-25 Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon ATE460479T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002279924 2002-09-25
JP2002377569 2002-12-26
PCT/JP2003/012280 WO2004029242A1 (ja) 2002-09-25 2003-09-25 フォンビルブランド因子特異的切断酵素に対する抗体及びそれを用いたアッセイ系

Publications (1)

Publication Number Publication Date
ATE460479T1 true ATE460479T1 (de) 2010-03-15

Family

ID=32044615

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03798512T ATE460479T1 (de) 2002-09-25 2003-09-25 Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon

Country Status (10)

Country Link
US (1) US7575872B2 (de)
EP (2) EP2157178A1 (de)
JP (3) JPWO2004029242A1 (de)
KR (1) KR101154550B1 (de)
CN (1) CN1701117B (de)
AT (1) ATE460479T1 (de)
AU (2) AU2003266632A1 (de)
CA (1) CA2499926C (de)
DE (1) DE60331666D1 (de)
WO (1) WO2004029242A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
CA2519258C (en) 2003-03-17 2014-04-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Construct comprising region recognized by antibody against von willebrand factor-specific cleaving protease
US20040185042A1 (en) * 2003-03-20 2004-09-23 Friedrich Scheiflinger Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies
KR20060123348A (ko) 2003-12-22 2006-12-01 가부시키가이샤 미쓰비시 가가쿠 야토론 본 윌브랜드 인자 분해효소의 측정에 의한 혈전병의검출방법
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
EP2322646B1 (de) 2004-11-08 2013-01-16 Mitsubishi Chemical Medience Corporation Verfahren zum Nachweis von Plättchenthrombose oder Organversagen
JP5067917B2 (ja) * 2005-12-28 2012-11-07 アルフレッサファーマ株式会社 Ａｄａｍｔｓ１３の分離精製方法
ES2373989T3 (es) 2006-01-31 2012-02-10 Mitsubishi Chemical Medience Corporation Procedimiento para la determinación del estado de un síndrome de coagulación intravascular diseminada.
CA2642546A1 (en) * 2006-02-16 2007-08-23 Mitsubishi Kagaku Iatron, Inc. Method for detection of condition in consciousness disorder patient and kit for the detection
JP2008136453A (ja) * 2006-12-05 2008-06-19 Mitsubishi Kagaku Iatron Inc フォンビレブランド因子切断酵素の活性阻害因子把握方法
EP2172544B1 (de) 2007-06-22 2014-11-12 The Chemo-Sero-Therapeutic Research Institute Neue adamts-13-mutante
ES2685503T3 (es) * 2008-12-05 2018-10-09 Baxalta GmbH Métodos de medida de la división in vivo de Factor von Willebrand mediada por ADAMTS13 y utilización de los mismos
JP2013040912A (ja) * 2011-08-18 2013-02-28 Miyazakiken Sangyo Shien Zaidan 成人ｔ細胞白血病診断器具
US11597778B2 (en) 2015-04-07 2023-03-07 The Trustees Of The University Of Pennsylvania Human monoclonal autoantibodies to ADAMTS13 and uses thereof
WO2017119498A1 (ja) * 2016-01-08 2017-07-13 国立大学法人京都大学 Ａｄａｍｔｓ１３を主成分とする診断薬および医薬品
CN106008715B (zh) * 2016-07-18 2019-11-08 苏州大学附属第一医院 一种抗人血管性血友病因子裂解酶的抑制性单克隆抗体及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049106A1 (en) * 2000-04-27 2001-12-06 Leonard Buckbinder ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
DE10034154A1 (de) * 2000-07-07 2002-01-24 Inst Polymerforschung Dresden Multifunktionelle Kopplungsagenzien mit zyklischen Iminoester- und Iminoethergruppen, Verfahren zu deren Herstellung und Verwendung
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2002279924A (ja) 2001-03-19 2002-09-27 Seiko Instruments Inc 大きな試料の観察・加工を可能とする集束イオンビーム装置
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
US7037658B2 (en) * 2001-08-16 2006-05-02 Regents Of University Of Michigan Methods and compositions for detecting variant ADAMTS13 genes

Also Published As

Publication number Publication date
US7575872B2 (en) 2009-08-18
CA2499926C (en) 2013-06-04
CA2499926A1 (en) 2004-04-08
EP1544293A4 (de) 2006-03-15
JP2013078319A (ja) 2013-05-02
CN1701117A (zh) 2005-11-23
AU2008202992A1 (en) 2008-07-31
AU2003266632A1 (en) 2004-04-19
DE60331666D1 (de) 2010-04-22
JPWO2004029242A1 (ja) 2006-01-26
EP1544293B1 (de) 2010-03-10
AU2008202992B2 (en) 2012-03-29
CN1701117B (zh) 2011-04-20
US20060251655A1 (en) 2006-11-09
JP2009236925A (ja) 2009-10-15
EP1544293A1 (de) 2005-06-22
KR20050048647A (ko) 2005-05-24
KR101154550B1 (ko) 2012-06-08
WO2004029242A1 (ja) 2004-04-08
EP2157178A1 (de) 2010-02-24

Similar Documents

Publication Publication Date Title
ATE460479T1 (de) Antikörper gegen ein den von-willebrand-faktor spezifisch spaltendes enzym und assay-system unter verwendung davon
Postma et al. N-Chlorosuccinimide, an efficient reagent for on-resin disulfide formation in solid-phase peptide synthesis
DE50306067D1 (de) Nachweis von tsh-rezeptor-autoantikörpern mit affinitätsgereinigten antikörpern
ATE159982T1 (de) Antikörper mit modifiziertem kohlenhydratgehalt und verfahren zur herstellung und verwendung
NO2010021I1 (no) Denosumab
BR9809443A (pt) Polipeptìdeo compreendendo uma porção antigênica de um antìgeno de m. tuberculosis, molécula de dna, vetor recombinante de expressão, célula hospedeira, processo para detecção de infecção de m. tuberculosis em uma amostra biológica, kit de diganóstico, anticorpo monoclonal, anticorpo policlonal, e, proteìna de fusão.
BRPI0416211A (pt) il-23 e seu receptor; reagentes relacionados e métodos
NO20071432L (no) Fremgangsmate for konsentrasjon av antistoffer of terapeutiske produkter derav.
DK1625163T3 (da) Fremgangsmåde til at påvise proBNP med en monoklonal antistofbinding til aminosyrerne 38-43
NO20025354L (no) Pattedyr-reseptorproteiner; beslektede reagenser og fremgangsmåter
CN109596839A (zh) 人和肽素快速定量检测方法与试剂盒
CN117343018B (zh) 一种甲氧苄啶半抗原、抗原、单克隆抗体及其磁珠微流控免疫检测方法与应用
Xu et al. Quality comparability assessment of a SARS-CoV-2-neutralizing antibody across transient, mini-pool-derived and single-clone CHO cells
BG106021A (bg) Метод за диагностика на трансмисивни спонгиозни енцефалопатии
DE69031726D1 (de) Antikörper, ihre Herstellung und Verwendung
JPS60155134A (ja) 体液中のだ液α―アミラーゼの存在下にすいぞうα―アミラーゼを特異的に測定するための試薬
CN117659171B (zh) 抗HBeAg抗体或其功能性片段、检测HBeAg的试剂和试剂盒
DE502004008729D1 (de) Gegen das Prothrombin-Fragment F1+2 gerichtete Antikörper, ihre Herstellung und Verwendung
US20230360747A1 (en) Improvements in or relating to quantitative analysis of samples
Dolan et al. Site-Specific Immobilization of Antibodies as a Platform Approach to Enable the Targeted Capture and Effective Removal of “Problematic” Host Cell Proteins (HCPs) from Complex Bioprocess Streams, Even at Sub-ppm Levels: Chinese Hamster Ovary (CHO) Phospholipase B-Like 2 (PLBL2)
Markely et al. A high‐throughput capillary isoelectric focusing immunoassay for fingerprinting protein sialylation
JP4153068B2 (ja) 蛍光免疫測定方法
DE60007195D1 (de) Antikörper und Diagnostizierverfahren zur Pestivirusdiagnose
ATE338764T1 (de) Vorrichtung von peptid- oder proteindarstellung, verfahren zu deren herstellung und deren verwendung
ATE140233T1 (de) Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1544293

Country of ref document: EP